Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 72

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 72
---
 provider and/or patient.The following table presents details regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”):

Three Months Ended September 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$81.8 $11.2 $93.0 $78.4 $12.1 $90.5 Tumor Profiling26.7 2.8 29.5 26.5 5.1 31.6 Prenatal44.5 — 44.5 43.4 0.1 43.5 Pharmacogenomics38.7 — 38.7 47.7 — 47.7 Total revenue$191.7 $14.0 $205.7 $196.0 $17.3 $213.3 

Nine months ended September 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$241.8 $33.8 $275.6 $235.6 $34.5 $270.1 Tumor Profiling81.0 9.2 90.2 77.1 18.0 95.1 Prenatal141.2 0.2 141.4 131.7 0.5 132.2 Pharmacogenomics107.5 — 107.5 129.6 — 129.6 Total revenue$571.5 $43.2 $614.7 $574.0 $53.0 $627.0 In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenue is further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Condensed Consolidated Statements of Operations and Comprehensive Loss